FDA-Approved for Type 2 Diabetes
Prescription via FirstCall
Ozempic®

Ozempic®

Semaglutide — FDA-approved for type 2 diabetes

Ozempic® (semaglutide) for type 2 diabetes — online physician evaluation and prescription. Blood sugar control, cardiovascular risk reduction, and weight benefit. Same-day evaluation, all 50 states.

Free physician evaluation and eligibility assessment
Insurance coverage assessment included
Board-certified physicians, all 50 states, 24/7
Cash-pay options available without coverage
Ongoing access for dose adjustments and monitoring
After physician evaluation
semaglutide 0.5mg, 1mg, or 2mg — weekly injection • Insurance assessment included

Prescription required. Provider determines clinical appropriateness.

A1C
Significant reduction in clinical trials
Weekly
Subcutaneous injection
CV
Cardiovascular risk reduction proven
24/7
Physician access
At a glance

Ozempic® (semaglutide) — for type 2 diabetes

Ozempic® is semaglutide FDA-approved for type 2 diabetes at doses up to 1mg weekly (the same molecule is approved for weight loss at the higher 2.4mg dose as Wegovy®). Beyond blood sugar control, Ozempic also reduces cardiovascular risk in adults with type 2 diabetes and established cardiovascular disease. Administered as a once-weekly subcutaneous injection. The FirstCall platform connects you with an independent, board-certified physician for evaluation and, when clinically appropriate, a prescription sent to a pharmacy of your choice.

Primary FDA indication
type 2 diabetes management; cardiovascular risk reduction
Administration
once-weekly subcutaneous injection (pre-filled pen)
Difference vs Wegovy®
Wegovy® is the same molecule approved at higher dose for weight loss

Educational content. Last clinically reviewed by the FirstCall Clinical Editorial Board, June 2026. The FirstCall platform provides access to independent, licensed physicians; final clinical decisions rest with the prescribing physician. Seek emergency care for severe abdominal pain, signs of pancreatitis, or severe allergic reaction.

The Medication

What is semaglutide (Ozempic®)?

Ozempic® is semaglutide — a GLP-1 receptor agonist FDA-approved for glycemic control in adults with type 2 diabetes, and to reduce the risk of major cardiovascular events in adults with type 2 diabetes and established cardiovascular disease. Available in 0.5mg, 1mg, and 2mg doses. Beyond blood sugar control, Ozempic® produces meaningful weight loss (average 5–10%) and has proven cardiovascular and kidney-protective benefits, making it one of the most clinically valuable diabetes medications currently available.

Comparing options: Ozempic® is frequently used off-label for weight loss, but Wegovy® (semaglutide 2.4mg) is the FDA-approved weight loss formulation at a higher dose. For patients whose primary goal is weight loss rather than diabetes management, the physician you're connected with will discuss which product is most appropriate for your clinical profile and insurance situation.

Ozempic®
Expected Results

What to expect on Ozempic®

Clinical trial averages — individual results vary.

Month1
Blood sugar improves

GLP-1 activity begins improving postprandial glucose control within the first weeks of treatment.

Month2–3
A1C reduction

Meaningful A1C reduction typically achieved by 2–3 months of consistent treatment.

Month3–6
Weight benefit

Average 5–10% body weight loss. Metabolic markers improving broadly.

Ongoing
Sustained control

Continued treatment maintains A1C control and provides cardiovascular protection long-term.

Eligibility

Who qualifies for Ozempic®?

Ozempic® is indicated for adults with type 2 diabetes for glycemic control, and for those with type 2 diabetes and established cardiovascular disease to reduce major cardiovascular events. The physician you're connected with will evaluate your diabetes history, current medications, kidney function, and cardiovascular profile.

BMI 30+ (obesity) — qualifies
BMI 27+ with a qualifying condition — qualifies
Qualifying conditions: type 2 diabetes, hypertension, dyslipidemia, sleep apnea, CVD
No personal or family history of MEN 2 or medullary thyroid cancer

The physician you're connected with will assess eligibility and help navigate insurance or cash-pay options at your free consultation.

Simple Process

How to get Ozempic® through FirstCall

1
Physician evaluation

Brief health intake including BMI, health history, and current medications. Free. Takes about 10 minutes.

2
Insurance assessment

Physician evaluates eligibility and assists with prior authorization or advises on cash-pay options.

3
Prescription and support

Prescription issued. Ongoing physician access for dose escalation, side effect management, and progress review.

Common Questions

Frequently asked questions

Everything you need to know about Ozempic® and how FirstCall works.

More questions?

Our care team is available 24/7.

Contact us ›
Ozempic® is FDA-approved for glycemic control in adults with type 2 diabetes, and to reduce the risk of major cardiovascular events in adults with type 2 diabetes and established cardiovascular disease.
Both contain semaglutide but are different products. Ozempic® is for type 2 diabetes (max 2mg dose). Wegovy® is for weight loss (2.4mg dose). Different FDA approvals and dosing schedules.
Ozempic® is frequently used off-label for weight loss. However, Wegovy® (semaglutide 2.4mg) is the FDA-approved weight loss product. Your physician will advise on the most appropriate prescription for your primary clinical goal.
Clinical trials showed average A1C reductions of 1–2%, meaningful fasting glucose improvements, and better post-meal control. Results vary by baseline A1C and other diabetes medications.
Ozempic® typically has better insurance coverage for type 2 diabetes than Wegovy® has for weight loss — most plans cover it with prior authorization. FirstCall can assist with the authorization process.
Important Safety Information

Ozempic® is contraindicated in patients with a personal or family history of medullary thyroid carcinoma or MEN 2. Do not use in type 1 diabetes or diabetic ketoacidosis. Common side effects include nausea, vomiting, diarrhea — particularly during dose escalation. Pancreatitis has been reported. When used with insulin or sulfonylureas, hypoglycemia risk increases. Do not use during pregnancy.

Other GLP-1 options

Your physician will recommend the most appropriate medication for your profile.

Wegovy®
Wegovy®
semaglutide for weight loss
Zepbound®
Zepbound®
tirzepatide — dual GIP/GLP-1
GLP-1 Programs
GLP-1 Programs
full program overview

Get your Ozempic® evaluation today.

Free physician consultation. Insurance assessment included.